BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked number 403 on Deloitte’s Technology Fast 500
BOTHELL, Wash., Nov. 19, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked number 403 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. BioLife Solutions’ revenue grew 233% from 2016 through 2019. Mike Rice, BioLife Solutions CEO, remarked, “We’ve built a class-defining portfolio of cell and gene therapy bioproduction tools. The regenerative medicine space is poised for significant growth over the next several years and BioLife is very well configured to become an even more critical and larger supplier to cell and gene therapy developers.” About Deloitte’s 2020 Technology Fast 500™ In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America. About BioLife Solutions Cautions Regarding Forward Looking Statements
Media & Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-ranked-403rd-fastest-growing-company-in-north-america-on-deloittes-2020-technology-fast-500-301176641.html SOURCE BioLife Solutions, Inc. | ||
Company Codes: NASDAQ-SMALL:BLFS |